XSHE
300206
Market cap1.04bUSD
Jul 10, Last price
12.04CNY
1D
-0.99%
1Q
-18.37%
Jan 2017
26.74%
IPO
95.38%
Name
Edan Instruments Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Edan Instruments, Inc. is a global provider specializing in the development, manufacturing, and worldwide distribution of a comprehensive range of medical equipment. Their diagnostic electrocardiograph (ECG) portfolio covers a variety of solutions, such as resting ECG, stress testing, Holter monitoring, wireless options, and dedicated ECG workstations. For patient monitoring, Edan offers systems addressing vital signs, transport, central monitoring, and various levels of care—from high acuity to acute and sub-acute settings—along with telemetry and pulse oximetry devices. In the field of obstetrics and gynecology, their offerings include fetal and maternal monitoring systems, fetal telemetry, ultrasonic Doppler devices, and video colposcopes. The company's ultrasound imaging systems encompass both color Doppler and black-and-white digital units. Additionally, Edan provides in-vitro diagnostics (IVD) like hematology analyzers, and a suite of point-of-care testing (POCT) systems, including analyzers for blood gas and chemistry, magnetic immunoassay, and colloidal gold-labeled immunoassay. They also cater to the veterinary market with specialized ultrasound, ECG, ABG, and monitoring products. Edan Instruments, Inc. maintains its headquarters in Shenzhen, People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||